Authorized: 300 million
Issued: 100 million
Float: 12-17 million
Shinn: 54 million
Tai Ho Chung: 8 million
CC Chung: 4 million
David Chai: 4 million
Bank (?): large holding (?)
Pharmaceutical Firm, ARTEC, Inc., Reports Moving On In The Development Of An Improved Tubercin™ And The Testing Of HIV/AIDS Human Patients In Africa
27 May 2010 - 22:00 PDT
ARTEC, Inc., (Pink Sheets: ATKJ), has improved Tubercin T-5 an immunostimulant. In the last two years, Artec asserts that Tubercin™ has improved significantly and tested in Africa, in the company's opinion, with positive results on human patients afflicted with HIV/AIDS. Under strict confidential conditions, the results received were most encouraging. Artec is engaged in full pursuit of obtaining FDA registration of Tubercin™ in Africa.
With ample funding, the success of Artec is within reach. The steady support of Artec's shareholders and associates has fostered its accomplishments. Artec thanks all the aforementioned for their loyalty and support.
Artec Inc. is a small entrepreneurial pharmaceutical company in a very competitive field of "Discovering Medicine" to curb HIV/AIDS and cancer. The costs involved are very steep and the challenges bordering on insurmountable. Artec has succeeded in coming this far where, in the company's opinion, significant research for many years and billions of dollars spent have not. Artec thanks its partner Dr. Tai Ho Chung, his son C.C. Chung and Kyungpook National University (Seoul, Korea) for the patented baseline research prototype, Tubercin™. T-5. Artec looks forward to working together with Dr. Chung and C.C. Chung to bring this improved Tubercin to the world. Artec's Leading Scientist, Dr. J.K. Park and his associates have also helped, in the company's view, improve the efficacy of the new Tubercin. Artec also thanks Dr. J.K. Park and everyone working under his leadership and in unison with his association with them.
Artec is serious about the future. The firm has recently explored such issues as Permanent Headquarters; High Volume Manufacturing of Tubercin; and Developing a Vaccine for Prevention of HIV/AIDS yet Impacting HIV/AIDS and cancer. Artec's progress in the next few months is considered critical for continued successes.
Artec is resolved to bring Tubercin to the market in the near future. Artec appreciates the continued support. The company will disclose more appropriate and specific information in the future. The confidential agreements do not afford Artec the liberty to disclose specific information at this time.
Pharmaceutical Firm, ARTEC, Inc., Announces Testing Launch of TUBERCIN(TM) -- Mission Focus is on the Testing of HIV/AIDS & Tuberculosis Patients in South Africa
Monday September 24, 2007 7:01 am ET
OKLAHOMA CITY--(BUSINESS WIRE)--ARTEC, Inc., (Pink Sheets: ATKJ - News), visionary pharmaceutical firm, has acquired the preliminary outline to be used for the testing protocol from a sponsoring scientific group in South Africa for TUBERCIN(TM), a revolutionary polysaccharide compound to be used as an HIV/AIDS and ANTI-CANCER immunostimulant.
"We are grateful to further test the medicinal impact of TUBERCIN(TM) in South Africa on their suffering patients," said Mr. Gerry Knight, Executive Vice-President of ARTEC, Inc. "Their dedicated partnership is enabling the launch testing of an immunostimulant we believe will greatly impact the devastation of HIV/AIDS, Tuberculosis and cancer worldwide. The continued assistance from our shareholders will also uphold our commitment to speedily developing TUBERCIN(TM) as a treatment that could soon bring hope to the millions suffering."
Early in October 2006, Dr. Ronald Shinn, President and Board of Directors Chairman of ARTEC, Inc. arrived in South Africa at the invitation of a group of prominent business and professional South Africans. Although previous in depth communications had occurred, the trip enabled both sides the face-to-face opportunity to explore the use of TUBERCIN(TM) on the devastating impact of HIV/AIDS in Africa. The problem of AIDS is horrendous especially when witnessing it first hand.
The Desperate Need for Relief of HIV/AIDS and Tuberculosis in South Africa is currently experiencing one of the most severe HIV/AIDS epidemics in the world. As reported by the World Health Organization, HIV and Tuberculosis form a lethal combination each speeding the other's progress. By the end of 2005, there were five and a half million people living with HIV in South Africa, and almost 1,000 AIDS deaths occurring every day.
The Company, together with the cooperation of Mr. Rodney Watson, Director of ARTEC, Inc. South Africa, has assembled a team of scientific personnel necessary for the South Africa FDA project. Emerging as the chief scientist for ARTEC, Inc. is Dr. Shawn Pruitt from the U.S.A. Dr. Pruitt and his colleagues have been working diligently in the development of information and materials on research needed for this project.
Recently, ARTEC, Inc. received the preliminary outline of the Testing Protocol to be used from the sponsoring scientific group in South Africa. It is advocating the testing of TUBERCIN(TM) on human patients in the hospital afflicted with AIDS and Tuberculosis. The testing will begin with under 100 patients. ARTEC, Inc. is working on this project as high priority and will provide more information as it becomes known.
In addition to working on the FDA project, Artec, Inc. has initiated direct contact with JSE Limited, formerly the Johannesburg Securities Exchange, and is in the process of establishing membership.
President Dr. Ronald Shinn has made a commitment, on behalf of ARTEC, Inc. to raise the necessary funding to combat HIV/AIDS in Africa and world wide. The Company appreciates the continued shareholders support!
ARTEC, Inc. intends to release further information on the progress of its product developments and integration. For more information on ARTEC, Inc., visit http://www.artec-inc.net .
Dr.Ronald Shinn 916-428-3458
Shapiro's Tubercin-virus patent filing - (WO/2006/078369)
Prior Art showing this to be old and NOT inventive
Protest info here
Hard to Treat Diseases v. Ronald Shinn 05-14737 04-80010 CV-DTKH 12-12-2006